← 返回

MSC 来源小细胞外囊泡的双重作用:胰腺导管腺癌抗肿瘤机制的调控见解

英文原题:Dual facets of MSC-derived small EVs: regulatory insights into antitumor mechanisms in pancreatic ductal adenocarcinoma.

查看英文原题

Dual facets of MSC-derived small EVs: regulatory insights into antitumor mechanisms in pancreatic ductal adenocarcinoma.

PubMed 2025/04/10(内容时间) Med Oncol Q2 · IF 4.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胰腺导管腺癌(PDAC)的特征是细胞外基质致密、纤维化、免疫抑制且促结缔组织增生。间充质干细胞(MSC)来源的细胞外囊泡(EV)已成为一种新兴治疗策略,但需审慎评估MSC-EV对肿瘤细胞可能产生的双重作用。

本研究旨在评估MSC-EV对PDAC的机制性影响。采用超速离心分离华通胶(WJ)MSC来源的小EV,并通过纳米颗粒跟踪分析和流式细胞术进行表征。将每个Panc-1细胞加入4000–10000个EV,先进行初步MTT实验;后续实验使用每个细胞4000、8000和12000个EV。培养24小时后进行凋亡和细胞周期分析,并检测上皮-间质转化(EMT)相关基因及免疫相关基因表达。对照组G1期细胞比例为31%,高于MSC-EV处理组的35%–36%。对照组存活细胞比例为80%,处理组约为78%–79%,各组凋亡分析结果相近。与对照组相比,处理组CD44、VIM、MMP9、TIMP1和ZEB1基因下调;CLDN1和CDH1在最低EV浓度下上调,在较高浓度下则下调。免疫基因分析显示,处理组促炎细胞因子(IL-6、TNF-α、IFN-γ、IL-1α、IL-1β)下调,抗炎细胞因子IL-10上调。

本研究揭示了WJ-MSC小EV在PDAC中的双重作用:其可抑制细胞增殖并调节EMT标志物,提示具有抗肿瘤潜力,但也呈现免疫抑制特征。这些结果既显示WJ-MSC小EV作为治疗剂的前景,也凸显其挑战,仍需进一步研究以优化应用并平衡其作用。

展开英文摘要原文

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense, fibrotic, immunosuppressive, and desmoplastic extracellular matrix. Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) have emerged as a novel therapeutic strategy. Nonetheless, the potential dual effects of MSC-EVs on tumor cells warrant careful consideration.

This study aimed to evaluate the mechanistic effects of MSC-EVs on PDAC. Wharton's Jelly (WJ) MSC-derived small EVs were isolated using ultracentrifugation method and analyzed through nanoparticle tracking analysis (NTA) and flow cytometry. EVs were added to Panc-1 cells at concentrations of 4000-10,000 EVs per cell, and a preliminary MTT assay was performed. In subsequent experiments, EVs were added to Panc-1 cells at concentrations of only 4000, 8000 and 12,000 EVs per cell. After 24 h, apoptosis and cell cycle analyses were performed. The expression of epithelial-mesenchymal transition (EMT)-related and immune-related genes was analyzed.

Cell cycle analysis showed higher G1 phase percentage in the control group (31%) compared to MSC EV-treated groups (35-36%). Apoptosis analysis revealed similar viable and necrotic cell percentages among the control (80% viable) and treated groups (approximately 78-79% viable). The CD44, VIM, MMP9, TIMP1, and ZEB1 genes were downregulated in treated groups compared to the control.

Although CLDN1 and CDH1 genes were upregulated at the lowest EV concentration, they were downregulated at higher EV concentrations. Immune gene analysis showed downregulation of pro-inflammatory cytokines (IL-6, TNF- , IFN- , IL-1 , IL-1 ) and upregulation of the anti-inflammatory cytokine IL-10 in treated groups.

This study revealed the dual role of WJ-MSC small EVs in PDAC. While they suppressed cell proliferation and modulated EMT markers, indicating their antitumor potential, they also exhibited an immunosuppressive profile.

These findings highlight both the promise and challenges of using WJ-MSC small EVs as therapeutic agents, necessitating further studies to optimize their application and balance their effects.

论文信息

作者
Kaçaroğlu D、Yaylacı S、Ulaşlı AM
单位
Faculty of Medicine, Department of Medical Biology, Lokman Hekim University, Söğütözü, 2179. Sk. No:6, 06530, Çankaya, Ankara, Turkey. demet.kacaroglu@lokmanhekim.edu.tr.Turkey
期刊
Medical oncology (Northwood, London, England)2025 Apr 10
原文标识
PubMed 40208413 · DOI 10.1007/s12032-025-02713-5